StockMacro
Company, fund or insider

Help

Menu

Baxter International

$25.39 +31% in 6 monthsMarket cap $13.1B

BAX on XNYS, Health Care, Baxter International Inc., job postings

Measures activity, not value. Not investment advice.

Shares up 46% in a year, but Baxter still lost $723M over 12 months on revenue up 5.3%.

  • GoodInstitutional holders up 8.3%, to 728 from 672 last quarter

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.

Industry
Surgical & medical instruments & apparatus (Health Care)
Employees
37,500
Website
baxter.com
Listed
NYSE, US
Last results
29 Oct 2026
Next results
expected around 11 Feb 2027 (an estimate: a year ago it reported on 12 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $3.1B, net income $294.0M.
Quarter to 31 Dec 2021: revenue $3.6B, net income $238.0MQuarter to 31 Dec 2021: revenue $3.6B, net income $238.0MQuarter to 31 Mar 2022: revenue $3.8B, net income $71.0MQuarter to 31 Mar 2022: revenue $3.8B, net income $71.0MQuarter to 30 Jun 2022: revenue $3.9B, net income $252.0MQuarter to 30 Jun 2022: revenue $3.9B, net income $252.0MQuarter to 30 Sep 2022: revenue $3.9B, net income -$2.9BQuarter to 30 Sep 2022: revenue $3.9B, net income -$2.9BQuarter to 31 Dec 2022: revenue $3.7B, net income $181.0MQuarter to 31 Dec 2022: revenue $3.7B, net income $181.0MQuarter to 31 Mar 2023: revenue $3.8B, net income $44.0MQuarter to 31 Mar 2023: revenue $3.8B, net income $44.0MQuarter to 30 Jun 2023: revenue $3.8B, net income -$141.0MQuarter to 30 Jun 2023: revenue $3.8B, net income -$141.0MQuarter to 30 Sep 2023: revenue $3.8B, net income $2.5BQuarter to 30 Sep 2023: revenue $3.8B, net income $2.5BQuarter to 31 Dec 2023: revenue $3.9B, net income $245.0MQuarter to 31 Dec 2023: revenue $3.9B, net income $245.0MQuarter to 31 Mar 2024: revenue $3.7B, net income $37.0MQuarter to 31 Mar 2024: revenue $3.7B, net income $37.0MQuarter to 30 Jun 2024: revenue $3.9B, net income -$314.0MQuarter to 30 Jun 2024: revenue $3.9B, net income -$314.0MQuarter to 30 Sep 2024: revenue $2.8B, net income $140.0MQuarter to 30 Sep 2024: revenue $2.8B, net income $140.0MQuarter to 31 Dec 2024: revenue $2.8B, net income -$512.0MQuarter to 31 Dec 2024: revenue $2.8B, net income -$512.0MQuarter to 31 Mar 2025: revenue $2.7B, net income $126.0MQuarter to 31 Mar 2025: revenue $2.7B, net income $126.0MQuarter to 30 Jun 2025: revenue $2.9B, net income $91.0MQuarter to 30 Jun 2025: revenue $2.9B, net income $91.0MQuarter to 30 Sep 2025: revenue $2.9B, net income -$46.0MQuarter to 30 Sep 2025: revenue $2.9B, net income -$46.0MQuarter to 31 Dec 2025: revenue –, net income -$1.1BQuarter to 31 Mar 2026: revenue $2.8B, net income -$15.0MQuarter to 31 Mar 2026: revenue $2.8B, net income -$15.0MQuarter to 30 Jun 2026: revenue $3.0B, net income $126.0MQuarter to 30 Jun 2026: revenue $3.0B, net income $126.0MQuarter to 30 Sep 2026: revenue $3.1B, net income $294.0MQuarter to 30 Sep 2026: revenue $3.1B, net income $294.0M
31 Dec 2021RevenueNet incomeNet losstallest bar $3.9B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$3.1B$294.0M
30 Jun 2026$3.0B$126.0M
31 Mar 2026$2.8B-$15.0M
31 Dec 2025–-$1.1B
30 Sep 2025$2.9B-$46.0M
30 Jun 2025$2.9B$91.0M
31 Mar 2025$2.7B$126.0M
31 Dec 2024$2.8B-$512.0M
30 Sep 2024$2.8B$140.0M
30 Jun 2024$3.9B-$314.0M
31 Mar 2024$3.7B$37.0M
31 Dec 2023$3.9B$245.0M
30 Sep 2023$3.8B$2.5B
30 Jun 2023$3.8B-$141.0M
31 Mar 2023$3.8B$44.0M
31 Dec 2022$3.7B$181.0M
30 Sep 2022$3.9B-$2.9B
30 Jun 2022$3.9B$252.0M
31 Mar 2022$3.8B$71.0M
31 Dec 2021$3.6B$238.0M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $12.0B $11.3B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +6.0% +13%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$723.0M -$341.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$1.42 -$0.66
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 29.2% 33.3% 60.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -1.8% -0.1% -8.3%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -6.0% -3.0% -10.1%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -10.5% -26.3%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $2.0B $1.7B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $844.0M $755.0M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$1.1B (net cash) -$971.0M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.13 0.31
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $12.57
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 28.0
P/SPrice to sales: market cap divided by revenue of the last 12 months. 1.1 2.3
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 1.0 2.5
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 2.0 2.8
Dividend yieldDividends per share declared in the latest fiscal year divided by the share price. 2.0% 1.4%

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Baxter InternationalBAX (this company) $13.1Bloss1.1+6.0%-6.0%
PenumbraPEN $12.6B80.18.1+17%10.1%
GlaukosGKOS $14.0Bloss20.3+47%-24.6%
SolventumSOLV $14.3B91.91.8-2.8%1.9%
InsuletPODD $9.2B21.52.9+26%13.4%
Globus MedicalGMED $8.9B16.12.9+13%17.8%

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+4.9%

$3.1B vs $2.9B (quarter ended 30 Sep 2026)

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+8.3%

728 13F filers vs 672

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

519.9M shares held by 13F filers (30 Sep 2026) of 517.3M outstanding (22 Oct 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

4.6%

23.7M shares sold short (30 Oct 2026) of 517.3M outstanding (22 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

3.0

23.7M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-0.4%

23.8M shares sold short in the report before, 23.7M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

48%

48% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 61%

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$1.5M

the 12 months before: $0

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$1.3M

4 quarters

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

23

23 articles in the last 7 days; its usual week has 4 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

5.8×

23 articles in the last 7 days; its usual week has 4.

Price $25.39 on 20 Nov 2026, +46% over 12 months (12-month range $15.80 to $28.35)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: $0).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 8 published in the last 12 months (none in the 12 months before).
Revenue per quarter. Revenue $3.1B in the latest quarter, +4.9% on a year earlier.
Capital spending per quarter. Capital spending $172.0M in the latest quarter, +23% on a year earlier.
Institutional holders (13F filers). 728 13F filers reported holding it in the latest 13F quarter, +6.9% on a year earlier.
Federal obligations. Federal obligations: $15.9M published in the last 12 months, +141% on the 12 months before.
Lobbying spend. Lobbying spend: $1.3M published in the last 12 months, -27% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
27 Aug 2026Lobbying filinglobbying engagement terminated (MCDERMOTT+ LLC)
19 Aug 20268-K and other filingsDirector or officer change
4 Aug 20268-K and other filingsDirector or officer change
21 Jul 2026Lobbying filingnew lobbying registration (SUMMIT HEALTH CARE CONSULTING)
8 May 20268-K and other filingsDirector or officer change
16 Mar 20268-K and other filingsDirector or officer change
12 Feb 20268-K and other filingsDirector or officer change
12 Feb 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
3 Feb 2026Sharp changeShort interest spike: short interest spike, 33.8M vs usual 18.7M (2026-01-15); 2.0x the same period a year earlier
16 Jan 2026Lobbying filinglobbying engagement terminated (CORNERSTONE GOVERNMENT AFFAIRS, INC.)
13 Jan 2026Sharp changeShort interest spike: short interest spike, 34.2M vs usual 18.3M (2025-12-31); 2.7x the same period a year earlier
30 Dec 2025Sharp changeShort interest spike: short interest spike, 33.5M vs usual 18.2M (2025-12-15); 2.6x the same period a year earlier
16 Dec 2025Sharp changeShort interest spike: short interest spike, 33.1M vs usual 18.0M (2025-11-28); 2.7x the same period a year earlier
4 Dec 20258-K and other filingsA major agreement ended
2 Dec 2025Sharp changeShort interest spike: short interest spike, 29.3M vs usual 17.6M (2025-11-14); 2.3x the same period a year earlier
12 Nov 20258-K and other filingsDirector or officer change
21 Oct 20258-K and other filingsDirector or officer change
21 Oct 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Oct 2025Sharp changeWikipedia attention spike: wikipedia attention spike, 5,189 vs usual 1,767.50 (2025-10-06..2025-10-12); 1.4x the same week a year earlier
7 Jul 20258-K and other filingsDirector or officer change
7 Jul 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Jun 20258-K and other filingsA major agreement ended
21 Apr 2025Lobbying filinglobbying engagement terminated (PORTERFIELD, FETTIG & SEARS, LLC)
3 Feb 20258-K and other filingsDirector or officer change
3 Feb 20258-K and other filingsDirector or officer change
3 Feb 20258-K and other filingsCompleted an acquisition or asset sale
31 Jan 20258-K and other filingsDirector or officer change
13 Dec 2024Lobbying filingnew lobbying registration (PORTERFIELD, FETTIG & SEARS, LLC)
22 Nov 20248-K and other filingsDirector or officer change
9 Sep 20248-K and other filingsDirector or officer change
3 Sep 20248-K and other filingsDirector or officer change
13 Aug 20248-K and other filingsDirector or officer change
13 Aug 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
9 May 20248-K and other filingsDirector or officer change
9 May 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
31 Oct 2023Sharp changeShort interest spike: short interest spike, 11.3M vs usual 6.5M (2023-10-13); 1.7x the same period a year earlier
3 Oct 20238-K and other filingsDirector or officer change
2 Oct 20238-K and other filingsCompleted an acquisition or asset sale
21 Aug 20238-K and other filingsDirector or officer change
20 Jul 2023Lobbying filinglobbying engagement terminated (CAPITOL COUNSEL LLC)
11 Jul 2023Lobbying filingnew lobbying registration (S-3 GROUP)
29 Jun 20238-K and other filingsDirector or officer change
9 May 20238-K and other filingsDirector or officer change
7 Mar 2023Sharp changeFederal obligations jump: federal obligations jump, 9.0M vs usual 31K in the same month of earlier years (2023-02-01..2023-02-28); 4.6x the same month a year earlier
14 Feb 20238-K and other filingsDirector or officer change
20 Jan 2023Lobbying filinglobbying engagement terminated (TARPLIN, DOWNS & YOUNG, LLC)
20 Jan 2023Lobbying filinglobbying engagement terminated (BAKER & HOSTETLER LLP)
6 Jan 20238-K and other filingsDirector or officer change
6 Jan 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 Jul 2022Lobbying filinglobbying engagement terminated (BROWNSTEIN HYATT FARBER SCHRECK, LLP)
25 May 2022Sharp changeFirst award from a new federal agency: first award from a new federal agency (Department of Veterans Affairs): HILL-ROM, INC.: new Department of Veterans Affairs contract 36C24522N0511 ($1,317,668)
6 May 20228-K and other filingsDirector or officer change
6 May 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Apr 2022Lobbying filingnew lobbying registration (BAKER & HOSTETLER LLP)
14 Apr 2022Lobbying filingnew lobbying registration (CAPITOL COUNSEL LLC)
13 Dec 20218-K and other filingsCompleted an acquisition or asset sale
13 Dec 20218-K and other filingsDirector or officer change
30 Nov 20218-K and other filingsDirector or officer change
30 Nov 2021Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Feb 2022: -$4.8M published
Month from 1 Mar 2022: -$299K published
Month from 1 Apr 2022: -$689K published
Month from 1 Jan 2023: -$2.7M published
Month from 1 Feb 2023: -$154K published
Month from 1 Mar 2023: -$147K published
Month from 1 Mar 2024: -$2.6M published
H-1B/E-3 applications certified
Quarter from 1 Oct 2026: 8 published
Revenue per quarter
Quarter ended 31 Dec 2021: $3.6B, +12% on a year earlier; public on 24 Feb 2022
Quarter ended 31 Mar 2022: $3.8B, +28% on a year earlier; public on 29 Apr 2022
Quarter ended 30 Jun 2022: $3.9B, +23% on a year earlier; public on 29 Jul 2022
Quarter ended 30 Sep 2022: $3.9B, +21% on a year earlier; public on 28 Oct 2022
Quarter ended 31 Dec 2022: $3.7B, +5.2% on a year earlier; public on 9 Feb 2024
Quarter ended 31 Mar 2023: $3.8B, -1.5% on a year earlier; public on 28 Apr 2023
Quarter ended 30 Jun 2023: $3.8B, -0.5% on a year earlier; public on 28 Jul 2023
Quarter ended 30 Sep 2023: $3.8B, -2.2% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $3.9B, +3.7% on a year earlier; public on 9 Feb 2024
Quarter ended 31 Mar 2024: $3.7B, -1.0% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $3.9B, +2.0% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $2.8B, -27% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $2.8B, -29% on a year earlier; public on 22 Feb 2025
Quarter ended 31 Mar 2025: $2.7B, -27% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $2.9B, -26% on a year earlier; public on 6 Aug 2025
Quarter ended 30 Sep 2025: $2.9B, +4.3% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Mar 2026: $2.8B, +2.8% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $3.0B, +5.1% on a year earlier; public on 31 Jul 2026
Quarter ended 30 Sep 2026: $3.1B, +4.9% on a year earlier; public on 30 Oct 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $235.0M; public on 24 Feb 2022
Quarter ended 31 Mar 2022: $140.0M, -18% on a year earlier; public on 29 Apr 2022
Quarter ended 30 Jun 2022: $171.0M, +8.2% on a year earlier; public on 29 Jul 2022
Quarter ended 30 Sep 2022: $168.0M, -6.1% on a year earlier; public on 28 Oct 2022
Quarter ended 31 Dec 2022: $200.0M, -15% on a year earlier; public on 10 Feb 2023
Quarter ended 31 Mar 2023: $172.0M, +23% on a year earlier; public on 28 Apr 2023
Institutional holders (13F filers)
31 Dec 2021 report: 1,022; public on 14 Feb 2022
31 Mar 2022 report: 1,066; public on 16 May 2022
30 Jun 2022 report: 1,000; public on 15 Aug 2022
30 Sep 2022 report: 913; public on 14 Nov 2022
31 Dec 2022 report: 918; public on 14 Feb 2023
31 Mar 2023 report: 880; public on 15 May 2023
30 Jun 2023 report: 893; public on 14 Aug 2023
30 Sep 2023 report: 822; public on 14 Nov 2023
31 Dec 2023 report: 841; public on 14 Feb 2024
31 Mar 2024 report: 876; public on 15 May 2024
30 Jun 2024 report: 826; public on 14 Aug 2024
30 Sep 2024 report: 837; public on 14 Nov 2024
31 Dec 2024 report: 773; public on 14 Feb 2025
31 Mar 2025 report: 791; public on 15 May 2025
30 Jun 2025 report: 735; public on 14 Aug 2025
30 Sep 2025 report: 681; public on 14 Nov 2025
31 Dec 2025 report: 676; public on 17 Feb 2026
31 Mar 2026 report: 640; public on 15 May 2026
30 Jun 2026 report: 672; public on 14 Aug 2026
30 Sep 2026 report: 728; public on 16 Nov 2026
Federal obligations
Month from 1 Dec 2021: $35K published
Month from 1 Jan 2022: $69K published
Month from 1 Feb 2022: $201 published
Month from 1 Mar 2022: $102K published
Month from 1 Apr 2022: $51K published
Month from 1 May 2022: $2.1M published
Month from 1 Jun 2022: $2.0M published
Month from 1 Jul 2022: $2.2M published
Month from 1 Aug 2022: $3.3M published
Month from 1 Sep 2022: $14.6M published
Month from 1 Oct 2022: $3.1M published
Month from 1 Nov 2022: $1.0M published
Month from 1 Dec 2022: $670K published
Month from 1 Jan 2023: $413K published
Month from 1 Feb 2023: $7.5M published
Month from 1 Mar 2023: $9.3M published
Month from 1 Apr 2023: $346K published
Month from 1 May 2023: $122K published
Month from 1 Jun 2023: $851K published
Month from 1 Jul 2023: $41K published
Month from 1 Aug 2023: $49K published
Month from 1 Sep 2023: $3.5M published
Month from 1 Oct 2023: $1.8M published
Month from 1 Nov 2023: $195K published
Month from 1 Dec 2023: $53K published
Month from 1 Jan 2024: $314K published
Month from 1 Feb 2024: $287K published
Month from 1 Mar 2024: $118K published
Month from 1 Apr 2024: $514K published
Month from 1 May 2024: -$163K published
Month from 1 Jun 2024: $9.0M published
Month from 1 Jul 2024: $342K published
Month from 1 Aug 2024: $41K published
Month from 1 Sep 2024: $919K published
Month from 1 Oct 2024: $1.1M published
Month from 1 Nov 2024: $62K published
Month from 1 Dec 2024: $621K published
Month from 1 Jan 2025: $61K published
Month from 1 Feb 2025: $231K published
Month from 1 Mar 2025: $212K published
Month from 1 Apr 2025: $3K published
Month from 1 May 2025: -$39K published
Month from 1 Jun 2025: $13K published
Month from 1 Jul 2025: -$42K published
Month from 1 Aug 2025: $222K published
Month from 1 Sep 2025: $25K published
Month from 1 Oct 2025: $785K published
Month from 1 Nov 2025: $4.5M published
Month from 1 Dec 2025: $106K published
Month from 1 Jan 2026: $222K published
Month from 1 Feb 2026: $115K published
Month from 1 Mar 2026: $184K published
Month from 1 Apr 2026: $48K published
Month from 1 May 2026: $110K published
Month from 1 Jun 2026: $570K published
Month from 1 Jul 2026: $125K published
Month from 1 Aug 2026: $14.4M published
Month from 1 Sep 2026: $24K published
Month from 1 Oct 2026: $46K published
Month from 1 Nov 2026: -$5K published
Lobbying spend
Quarter from 1 Jan 2022: $570K published
Quarter from 1 Apr 2022: $670K published
Quarter from 1 Jul 2022: $630K published
Quarter from 1 Oct 2022: $670K published
Quarter from 1 Jan 2023: $580K published
Quarter from 1 Apr 2023: $970K published
Quarter from 1 Oct 2023: $420K published
Quarter from 1 Jan 2024: $380K published
Quarter from 1 Apr 2024: $350K published
Quarter from 1 Jul 2024: $410K published
Quarter from 1 Oct 2024: $470K published
Quarter from 1 Jan 2025: $970K published
Quarter from 1 Apr 2025: $420K published
Quarter from 1 Oct 2025: $390K published
Quarter from 1 Jan 2026: $370K published
Quarter from 1 Apr 2026: $280K published
Quarter from 1 Jul 2026: $650K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market selling (USD, Form 4) at $2.6M (5 Mar 2024), 6.2× its normal reading; higher than 78% of its own history.
  • Insider net buying (open market): Insiders bought a net $0 in the last 12 months (the 12 months before: $0).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 8 published in the last 12 months (none in the 12 months before).
  • Revenue per quarter: Revenue $3.1B in the latest quarter, +4.9% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 94 insider trades

No trades in the last 90 days; the latest was filed 5 Mar 2024. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
5 Mar 2024Jeanne K MasonEVP, Chief HR OfficerSellplanned in advance (10b5-1); after exercising options64,488$40.61$2.6MForm 4
22 Mar 2023Albert P L StrouckenDirectorSellafter exercising options3,930$37.52$147KForm 4
23 Feb 2023Jacqueline KunzlerSVP, Chief Quality OfficerSellafter exercising options3,813$40.50$154KForm 4
19 Jan 2023Jeanne K MasonSVP, Human ResourcesSellafter exercising options59,477$44.70$2.7MForm 4
7 Apr 2022Albert P L StrouckenDirectorSellafter exercising options4,020$76.02$306KForm 4
7 Apr 2022Peter S HellmanDirectorSellafter exercising options4,020$76.02$306KForm 4
5 Apr 2022John D ForsythDirectorSellafter exercising options1,005$77.68$78KForm 4
3 Mar 2022John D ForsythDirectorSellafter exercising options1,005$84.82$85KForm 4

728 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 116 opened a position, 61 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.65.5M12.7%$1.6B-16.3M-20%
Pzena Investment Management LLC62.4M12.1%$1.5B-2.9M-4.4%
Dodge & Cox55.7M10.8%$1.3B-2.7M-4.7%
FMR LLC (Fidelity)51.5M9.95%$1.2B-2.5M-4.5%
Vanguard Capital Management LLC33.9M6.55%$813.7M+152K+0.4%
Vanguard Portfolio Management LLC23.4M4.53%$562.0M-642K-2.7%
State Street Corp20.6M3.99%$495.2M+24K+0.1%
Geode Capital Management, LLC13.9M2.69%$333.8M-191K-1.4%
Greenhaven Associates Inc12.4M2.40%$297.5M-1.9M-13%
Invesco Ltd.11.3M2.18%$271.2M-1.1M-8.6%

Federal contracts

All 5 federal contracts

No new award in 12 months; the latest was signed 27 Aug 2025. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
27 Aug 2025Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response$4.4Mup to $64.9MSODIUM CHLORIDE (NACL), 0.9% FOR INJECTION, 100ML SOLUTION FLEXI-BAGUSAspending
28 Feb 2023Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response$9.2MTO PROCURE PHARMACEUTICAL PRODUCTS - DEXTROSE, LACTATED RINGERS INJECTION, LEVOPHED (NOREPINEPHRINE), SODIUM CHLORIDE (NACL), AND SODIUM CHLORIDE FOR INJ.USAspending
19 May 2022Department of Veterans Affairs$1.3MEMERGENCY PROCUREMENT OF ACUTE CARE BEDSUSAspending
1 Jun 2020Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response$5.4Mup to $29.6MSALINE IV UNITS 0.9% SODIUM CHLORIDE INJECTION, USP, 1000 MLUSAspending
24 Sep 2019Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response$8.5MPRALIDOXIME BUYUSAspending

Company events

All 74 company events

In 12 months: 5 director or officer changes, 3 major agreements, 1 agreement ended. Results releases and routine reports are left out.

FiledWhat happenedSource
19 Aug 2026Director or officer change8-K
18 Aug 2026Signed a major agreement8-K
4 Aug 2026Director or officer change8-K
8 May 2026Director or officer changeSame filing: changed its bylaws or fiscal year, shareholder vote results8-K
16 Mar 2026Director or officer change8-K
12 Feb 2026Director or officer change8-K
4 Dec 2025Signed a major agreement; A major agreement endedSame filing: took on new debt8-K
25 Nov 2025Signed a major agreement8-K

Reported lobbying spend: $270K in Q3 2026, $380K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
31 Jul 2026EndedMcdermott+ LLCfor Baxter InternationalReimbursement, coding and coverage for inpatient and outpatient products.Medicare/Medicaid, Health issuesFiling
30 Apr 2026NewSummit Health Care Consultingfor Baxter Healthcare CorporationParenteral nutrition Breast reconstruction surgeryHealth issuesFiling
31 Dec 2025EndedCornerstone Government Affairs, Inc.for Baxter Healthcare CorporationIssues related to the Labor, Health & Human Services Appropriations bill.BudgetFiling
31 Mar 2025EndedPorterfield, Fettig & Sears, LLCfor Baxter Healthcare CorporationGeneral issues related to providing quality kidney care services in other countries.; General issues related to home dialysis and other elements of quality kidney care, including remote patient monitoring.FOR, Health issuesFiling
29 Oct 2024NewPorterfield, Fettig & Sears, LLCfor Baxter Healthcare CorporationFederal policy related to kidney health.Health issuesFiling
1 May 2023EndedCapitol Counsel LLCfor Baxter Healthcare CorporationMonitor funding issues related to Presidents Proposed Budget and Senate and House Appropriations, including Labor, Health and Human Services and community project funding process.; Monitor issues related to supply chain challenges, medical device and pharmaceutical industry, price transparency and drug pricing, drug shortages, CHIPS and Science Act of 2022 (P.L. No: 117-167) implementation, healthcare workforce challenges, artificial intelligence, safe mobility issues, includi; Regulatory and reimbursement policy issues relating to healthcare programs, including Medicare and Medicaid coverage and reimbursement, safe mobility issues, diabetes and diabetic retinopathy, monitor medical device, drug pricing, supply chain, innovation, and provider issues. Monitor issues regardiBudget, Health issues, Medicare/MedicaidFiling
1 May 2023NewS-3 Groupfor Baxter Healthcare CorporationIssues relating to home dialysis and safe mobility; issues relating to pandemic all-hazards preparedness act; promote kidney care and positive patient outcomesHealth issues, MEDFiling
31 Dec 2022EndedTarplin, Downs & Young, LLCfor BaxterESRD, innovation, Medicare coverage and reimbursement, new tech add-on, kidney care demonstrations, Kidney Rx, home dialysis; H.R. 5376, the Inflation Reduction Act S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 H.R.2617, Consolidated Appropriations Act, 2023Medicare/Medicaid, Health issuesFiling

Layoff notices

All 8 layoff notices

No notice in 12 months; the latest is dated 23 Mar 2012. State WARN notices.

NoticeSiteWorkersJobs endSource
23 Mar 2012Baxter Healthcare Corp.Lake County, IL611 Mar 2012closureNotice
1 Jun 2010WELCH ALLYNBRANCHBURG, NJ1481 Aug 2010Notice
1 Aug 2004BAXTER HEALTHCARENO. BRUNSWICK, NJ4230 Jul 2004Notice
1 Jun 2004BAXTER HEALTHCARENO. BRUNSWICK, NJ4230 Jul 2004Notice
23 Sep 1998Baxter Healthcare CorporationLake County, IL611 Nov 1998closureNotice
20 Jun 1994Baxter Healthcare Corp.Cook County, IL170Not statedclosureNotice
28 Dec 1993Baxter Healthcare Corp.Lake County, IL0Not statedlayoffNotice
9 Feb 1990Baxter Healthcare Corp.Lake County, IL5311 May 1990layoffNotice

The 5 newest of 271 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 27 Aug 2026Lobbying record

    BAXTER INTERNATIONAL: lobbying engagement terminated (MCDERMOTT+ LLC) (dated 31 Jul 2026)

  2. 19 Aug 2026Filings record

    Director or officer change

  3. 4 Aug 2026Filings record

    Director or officer change

  4. 21 Jul 2026Lobbying record

    BAXTER HEALTHCARE CORPORATION: new lobbying registration (SUMMIT HEALTH CARE CONSULTING) (dated 30 Apr 2026)

  5. 8 May 2026Filings record

    Director or officer change

  6. 16 Mar 2026Filings record

    Director or officer change

  7. 12 Feb 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  8. 12 Feb 2026Filings record

    Director or officer change

  9. 28 Jan 2026Short interest and volume change

    had 33.8M shares sold short in the 15 Jan 2026 report, 2.0× the same report last year.

    Same report last year: 16.7M; its normal report is 18.7M.

    See the evidence
    This period
    33.8M (the 15 Jan 2026 report)
    Normal report (median of 24 earlier)
    18.7M
    Typical spread (median absolute deviation)
    2.6M
    How far from its usual level
    +3.8
    Same report last year
    16.7M
    History used
    2,939 days
    2025-01-15: 16.7M2025-01-31: 17.4M2025-02-14: 17.8M2025-02-28: 21.0M2025-03-14: 18.3M2025-03-31: 18.2M2025-04-15: 17.3M2025-04-30: 17.4M2025-05-15: 15.1M2025-05-30: 15.7M2025-06-13: 17.1M2025-06-30: 17.2M2025-07-15: 18.4M2025-07-31: 19.1M2025-08-15: 23.1M2025-08-29: 23.2M2025-09-15: 23.9M2025-09-30: 27.2M2025-10-15: 26.4M2025-10-31: 25.4M2025-11-14: 29.3M2025-11-28: 33.1M2025-12-15: 33.5M2025-12-31: 34.2M2026-01-15: 33.8M
    the 15 Jan 2026 report24 earlier reportsnormal: 18.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 16 Jan 2026Lobbying record

    BAXTER HEALTHCARE CORPORATION: lobbying engagement terminated (CORNERSTONE GOVERNMENT AFFAIRS, INC.) (dated 31 Dec 2025)

  11. 13 Jan 2026Short interest and volume change

    had 34.2M shares sold short in the 31 Dec 2025 report, 2.7× the same report last year.

    Same report last year: 12.8M; its normal report is 18.3M.

    See the evidence
    This period
    34.2M (the 31 Dec 2025 report)
    Normal report (median of 24 earlier)
    18.3M
    Typical spread (median absolute deviation)
    2.6M
    How far from its usual level
    +4.0
    Same report last year
    12.8M
    History used
    2,924 days
    2024-12-31: 12.8M2025-01-15: 16.7M2025-01-31: 17.4M2025-02-14: 17.8M2025-02-28: 21.0M2025-03-14: 18.3M2025-03-31: 18.2M2025-04-15: 17.3M2025-04-30: 17.4M2025-05-15: 15.1M2025-05-30: 15.7M2025-06-13: 17.1M2025-06-30: 17.2M2025-07-15: 18.4M2025-07-31: 19.1M2025-08-15: 23.1M2025-08-29: 23.2M2025-09-15: 23.9M2025-09-30: 27.2M2025-10-15: 26.4M2025-10-31: 25.4M2025-11-14: 29.3M2025-11-28: 33.1M2025-12-15: 33.5M2025-12-31: 34.2M
    the 31 Dec 2025 report24 earlier reportsnormal: 18.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 25 Dec 2025Short interest and volume change

    had 33.5M shares sold short in the 15 Dec 2025 report, 2.6× the same report last year.

    Same report last year: 13.1M; its normal report is 18.2M.

    See the evidence
    This period
    33.5M (the 15 Dec 2025 report)
    Normal report (median of 24 earlier)
    18.2M
    Typical spread (median absolute deviation)
    2.6M
    How far from its usual level
    +3.9
    Same report last year
    13.1M
    History used
    2,908 days
    2024-12-13: 13.1M2024-12-31: 12.8M2025-01-15: 16.7M2025-01-31: 17.4M2025-02-14: 17.8M2025-02-28: 21.0M2025-03-14: 18.3M2025-03-31: 18.2M2025-04-15: 17.3M2025-04-30: 17.4M2025-05-15: 15.1M2025-05-30: 15.7M2025-06-13: 17.1M2025-06-30: 17.2M2025-07-15: 18.4M2025-07-31: 19.1M2025-08-15: 23.1M2025-08-29: 23.2M2025-09-15: 23.9M2025-09-30: 27.2M2025-10-15: 26.4M2025-10-31: 25.4M2025-11-14: 29.3M2025-11-28: 33.1M2025-12-15: 33.5M
    the 15 Dec 2025 report24 earlier reportsnormal: 18.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  13. 10 Dec 2025Short interest and volume change

    had 33.1M shares sold short in the 28 Nov 2025 report, 2.7× the same report last year.

    Same report last year: 12.4M; its normal report is 18.0M.

    See the evidence
    This period
    33.1M (the 28 Nov 2025 report)
    Normal report (median of 24 earlier)
    18.0M
    Typical spread (median absolute deviation)
    2.6M
    How far from its usual level
    +3.9
    Same report last year
    12.4M
    History used
    2,891 days
    2024-11-29: 12.4M2024-12-13: 13.1M2024-12-31: 12.8M2025-01-15: 16.7M2025-01-31: 17.4M2025-02-14: 17.8M2025-02-28: 21.0M2025-03-14: 18.3M2025-03-31: 18.2M2025-04-15: 17.3M2025-04-30: 17.4M2025-05-15: 15.1M2025-05-30: 15.7M2025-06-13: 17.1M2025-06-30: 17.2M2025-07-15: 18.4M2025-07-31: 19.1M2025-08-15: 23.1M2025-08-29: 23.2M2025-09-15: 23.9M2025-09-30: 27.2M2025-10-15: 26.4M2025-10-31: 25.4M2025-11-14: 29.3M2025-11-28: 33.1M
    the 28 Nov 2025 report24 earlier reportsnormal: 18.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 4 Dec 2025Filings record

    A major agreement ended

  15. 26 Nov 2025Short interest and volume change

    had 29.3M shares sold short in the 14 Nov 2025 report, 2.3× the same report last year.

    Same report last year: 12.8M; its normal report is 17.6M.

    See the evidence
    This period
    29.3M (the 14 Nov 2025 report)
    Normal report (median of 24 earlier)
    17.6M
    Typical spread (median absolute deviation)
    2.2M
    How far from its usual level
    +3.5
    Same report last year
    12.8M
    History used
    2,877 days
    2024-11-15: 12.8M2024-11-29: 12.4M2024-12-13: 13.1M2024-12-31: 12.8M2025-01-15: 16.7M2025-01-31: 17.4M2025-02-14: 17.8M2025-02-28: 21.0M2025-03-14: 18.3M2025-03-31: 18.2M2025-04-15: 17.3M2025-04-30: 17.4M2025-05-15: 15.1M2025-05-30: 15.7M2025-06-13: 17.1M2025-06-30: 17.2M2025-07-15: 18.4M2025-07-31: 19.1M2025-08-15: 23.1M2025-08-29: 23.2M2025-09-15: 23.9M2025-09-30: 27.2M2025-10-15: 26.4M2025-10-31: 25.4M2025-11-14: 29.3M
    the 14 Nov 2025 report24 earlier reportsnormal: 17.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  16. 12 Nov 2025Filings record

    Director or officer change

  17. 21 Oct 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  18. 21 Oct 2025Filings record

    Director or officer change

  19. 14 Oct 2025Attention change

    drew 5,189 Wikipedia page views in the week of 6 Oct 2025, 1.4× the same week last year.

    Same week last year: 3,705; its normal week is 1,768.

    See the evidence
    This period
    5,189 (the week of 6 Oct 2025)
    Normal week (median of 26 earlier)
    1,768
    Typical spread (median absolute deviation)
    132
    How far from its usual level
    +17.1
    Same week last year
    3,705
    History used
    2,476 days
    2025-04-07: 1,8152025-04-14: 1,6982025-04-21: 1,7202025-04-28: 1,7142025-05-05: 1,6412025-05-12: 1,6292025-05-19: 1,9062025-05-26: 1,8342025-06-02: 1,6512025-06-09: 1,6642025-06-16: 1,6222025-06-23: 1,7102025-06-30: 1,5062025-07-07: 1,9502025-07-14: 1,6652025-07-21: 1,8592025-07-28: 1,9192025-08-04: 1,6962025-08-11: 1,6482025-08-18: 2,7152025-08-25: 2,2602025-09-01: 3,7122025-09-08: 3,2562025-09-15: 3,4832025-09-22: 3,3262025-09-29: 3,4782025-10-06: 5,189
    the week of 6 Oct 202526 earlier weeksnormal: 1,768

    Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

    Check it at the source: Wikimedia page view statistics.

  20. 2 Sep 2025Government contracts record

    BAXTER HEALTHCARE CORPORATION: new Department of Health and Human Services contract 75A50325C00013 ($4.4M) (dated 27 Aug 2025)

  21. 7 Jul 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  22. 7 Jul 2025Filings record

    Director or officer change

  23. 12 Jun 2025Filings record

    A major agreement ended

  24. 21 Apr 2025Lobbying record

    BAXTER HEALTHCARE CORPORATION: lobbying engagement terminated (PORTERFIELD, FETTIG & SEARS, LLC) (dated 31 Mar 2025)

  25. 3 Feb 2025Filings record

    Director or officer change

  26. 3 Feb 2025Filings record

    Director or officer change

  27. 3 Feb 2025Filings record

    Completed an acquisition or asset sale

  28. 31 Jan 2025Filings record

    Director or officer change

  29. 13 Dec 2024Lobbying record

    BAXTER HEALTHCARE CORPORATION: new lobbying registration (PORTERFIELD, FETTIG & SEARS, LLC) (dated 29 Oct 2024)

  30. 22 Nov 2024Filings record

    Director or officer change

  31. 9 Sep 2024Filings record

    Director or officer change

  32. 3 Sep 2024Filings record

    Director or officer change

  33. 13 Aug 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  34. 13 Aug 2024Filings record

    Director or officer change

  35. 9 May 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  36. 9 May 2024Filings record

    Director or officer change

  37. 14 Nov 2023Institutional holdings record

    Dodge & Cox opened a $372.0M position (2023Q3 13F)

  38. 25 Oct 2023Short interest and volume change

    had 11.3M shares sold short in the 13 Oct 2023 report, 1.7× the same report last year.

    Same report last year: 6.5M; its normal report is 6.5M.

    See the evidence
    This period
    11.3M (the 13 Oct 2023 report)
    Normal report (median of 24 earlier)
    6.5M
    Typical spread (median absolute deviation)
    833K
    How far from its usual level
    +3.9
    Same report last year
    6.5M
    History used
    2,114 days
    2022-10-14: 6.5M2022-10-31: 6.6M2022-11-15: 5.1M2022-11-30: 4.1M2022-12-15: 5.7M2022-12-30: 7.4M2023-01-13: 7.0M2023-01-31: 4.9M2023-02-15: 3.7M2023-02-28: 4.2M2023-03-15: 6.4M2023-03-31: 9.3M2023-04-14: 7.3M2023-04-28: 6.0M2023-05-15: 5.7M2023-05-31: 5.2M2023-06-15: 5.3M2023-06-30: 7.2M2023-07-14: 7.0M2023-07-31: 7.8M2023-08-15: 6.5M2023-08-31: 7.2M2023-09-15: 7.3M2023-09-29: 8.9M2023-10-13: 11.3M
    the 13 Oct 2023 report24 earlier reportsnormal: 6.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  39. 3 Oct 2023Filings record

    Director or officer change

  40. 2 Oct 2023Filings record

    Completed an acquisition or asset sale

Showing the newest 40 of 143 entries; narrow the window or the kind of data to see older ones.

Not listed: 237 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000010456
Ticker
BAX
Domain
baxter.com
Employer name
baxter healthcare, baxter healthcare corporation usa, Hill-Rom Services, Inc., Welch Allyn, Inc. (4 unverified)
Fein
02-0623407, 51-0357576 (2 unverified)
Hq location
IL|DEERFIELD|60015 (1 unverified)
Lobbying client
baxter, baxter healthcare, baxter international, welch allyn
Name
Baxter Belgium SPRL, Baxter Deutschland GmbH, Baxter Distribution Center Europe SA, Baxter Healthcare Corporation and 24 more
Uei
HAV8K5BJLTS9, RSKLEFCZ6127
Wikidata
Q761965
Wikipedia
Baxter International
  • DOL H-1B labor condition applications and PERM certifications36 data points9 Feb 2026 to 21 Sep 2026
  • Federal lobbying disclosures (LDA)68 records, 279 data points30 Dec 1950 to 30 Sep 2026
  • SEC Form 13F institutional holdings6 records, 481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)199 records11 Jan 2016 to 29 Oct 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1309 data points31 Dec 2006 to 22 Oct 2026
  • SEC Form 4 insider transactions94 records, 312 data points16 Feb 2016 to 5 Mar 2024
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards5 records, 3093 data points8 Mar 2010 to 18 Nov 2026
  • WARN layoff notices (state labor agencies)8 records, 24 data points5 Feb 1990 to 23 Mar 2012
  • Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026